Biotech Analyst Roundup: The Latest Bullish and Bearish Calls Across IBRX, SMMT, KURA, IRWD, AVXL, TGTX, CGEM and NTRA

Biotech remains one of the most catalyst-driven corners of the equity market, and the latest analyst commentary shows a sharp divide between companies where commercial execution is beginning to validate the pipeline and those where valuation, clinical uncertainty or financing needs remain major obstacles.

This week’s roundup covers ImmunityBio (IBRX), Summit Therapeutics (SMMT), Kura Oncology (KURA), Ironwood Pharmaceuticals (IRWD), Anavex Life Sciences (AVXL), TG Therapeutics (TGTX), Cullinan Therapeutics (CGEM) and Natera (NTRA).

The key takeaway: commercial traction is becoming increasingly important in biotech valuation, while companies still dependent on binary clinical or regulatory outcomes face a much higher burden of proof.

ImmunityBio (IBRX): Commercial Progress vs. Valuation Risk

Analyst stance: Cautious / Bearish

ImmunityBio continues to generate encouraging commercial momentum for ANKTIVA, but the latest bearish thesis argues that the market may already be assigning too much value to the asset.

The company recently reported another strong quarter for ANKTIVA, with Q2 net product revenue of approximately $50.7 million. Zacks noted that the product delivered its eighth consecutive quarter of sequential revenue growth since launch and that Q2 earnings and sales exceeded expectations.

The regulatory pipeline also remains important. The FDA has accepted the supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive papillary-only non-muscle-invasive bladder cancer, with a January 6, 2027 PDUFA date.

However, the bearish argument is that this indication may not dramatically alter the company’s valuation because the incremental revenue opportunity could be relatively modest.

The much bigger opportunity would be expansion into BCG-naïve NMIBC, but that thesis remains dependent on pivotal clinical data and the availability of BCG.

The valuation debate is therefore becoming increasingly important. The bearish analysis cited in this roundup estimates ANKTIVA’s NMIBC opportunity at roughly $3 billion in NPV, compared with a company valuation around $8 billion.

What analysts are watching

• ANKTIVA commercial adoption
• BCG-naïve NMIBC data
• FDA regulatory expansion
• Cash burn and funding requirements
• Potential dilution
• Whether revenue growth can justify the existing valuation

Bottom line: IBRX has transformed from a pure development-stage biotech into a company with meaningful commercial revenue. The question now is whether ANKTIVA’s eventual addressable market is large enough to justify the premium investors are paying today.